Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 3Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Peripheral Blood Stem Cell Transplantation 38fludarabine phosphate 37Cyclophosphamide 33Mycophenolic Acid 28Whole-Body Irradiation 24Cyclosporine 24Tacrolimus 22Radiotherapy 19Methotrexate 18Busulfan 18Antilymphocyte Serum 17Filgrastim 14Etoposide 14Vorinostat 11Bortezomib 11Bexarotene 11Methylprednisolone 10Lenalidomide 10pembrolizumab 9Rituximab 9Melphalan 9Gemcitabine 9Flow Cytometry 9Brentuximab Vedotin 9romidepsin 8mogamulizumab 8Methoxsalen 8fludarabine 7Magnetic Resonance Spectroscopy 7Cord Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mycosis Fungoides × AFM13 × Clear all
NCT04074746 2025-09-30

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

M.D. Anderson Cancer Center

Phase 1/2 Completed
45 enrolled
Lymphoid

Mycosis Fungoides, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡